Navigation Links
ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.

CHICAGO, July 7 /PRNewswire/ -- ICAP Ocean Tomo, the intellectual property brokerage division of ICAP plc (IAP.L), is offering for sale a patent portfolio related to the advanced drug formulation technology Captisol® owned by CyDex Pharmaceuticals Inc. The portfolio contains two US-issued patents and fifteen related foreign counterparts covering two important close-to-market, 505(b)(2), Captisol-enabled product opportunities: Captisol-enabled Fosphenytoin and Captisol-enabled Propofol.  



The advanced drug technology of CyDex's Captisol® is based on a modified cyclodextrin molecule that enables the creation of new products by significantly improving the solubility, stability, bioavailability, safety, and dosing of active pharmaceutical ingredients. Captisol-enabled™ Fosphenytoin is the advanced formulation of Fosphenytoin which is approved in the US for the short term treatment of epilepsy. This formulation offers advantages over the traditional product as it lowers pH and enables storage of the product at room temperature for up to two years. Captisol-enabled™ Propofol is an improved formulation over Propofol, an injectable general anesthetic. This formulation enhances the stability, reliability, and effectiveness of Propofol while reducing the potential for pain and allergic response. Unlike existing formulations, Captisol-enabled™ Propofol is pharmaceutically stable and does not degrade with exposure to light, oxidation, or the presence of divalent or trivalent cations.

"Both of these Captisol-enabled opportunities are very close to market and should be considered valuable assets to pharmaceutical manufacturers, distributors, branded generic companies, or specialty pharma companies looking to enhance their product offering, including those companies focused on injectable product opportunities," said Dean Becker, ICAP Ocean Tomo CEO.

To learn more about the patents available for sale in this portfolio or how to sell or buy intellectual property please contact Cameron Gray, Senior Vice President, ICAP Ocean Tomo at 650-421-3089 or at

About ICAP Ocean Tomo LLC

ICAP Ocean Tomo is the intellectual property brokerage division of ICAP.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP is also the source of global market information and research for professionals in the international financial markets. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
2. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
3. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
4. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
5. Now Offers Over 1,000 Medications Under $25 Bringing Increased Affordability to Consumers
6. BSGI Offers Improved Cancer Detection for Negative or Indeterminate Mammograms
7. In the Face of Pain® Offers Social Media 101 for Pain Management Advocates
8. Offers Fathers Day Discounts to Ensure this Fathers Day is a Healthy One
9. Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment
10. Gold Standard/Elsevier Offers Timely, Transparent, Reliable Drug Pricing Data, Including Average Wholesale Price (AWP)
11. Blog Contest Offers Graduate Students the Chance to Win a Trip to Zambia
Post Your Comments:
(Date:12/1/2015)... , Dec. 01, 2015 ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ... "Veterinary Equipment and Disposables Market by product, ... report to their offering. --> Research ...
(Date:12/1/2015)... 2015 CytRx Corporation (NASDAQ: CYTR ), ... today announced that it has reached its enrollment target ... 3 clinical trial of aldoxorubicin in patients with previously ... be completed in Q1 2016. The Phase 3 trial is ... Protocol Assessment from the FDA at 79 sites in ...
(Date:12/1/2015)... , Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), ... commercialization of therapies for cardiovascular conditions via the inhalation ... business in Australia . InCarda is ... Australia in the first half ... and medical centers in Adelaide ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The ... the important role that meat and poultry play in a healthy, balanced diet. ... nutrition quiz where visitors can check their “meat IQ,” a section offering straight ...
(Date:12/1/2015)... ... 01, 2015 , ... Integrated Rental Services (“Integrated Rental”), a ... LLC (“JII”). , With support from JII, Integrated Rental is poised for expansion ... centers, clinics, research labs and medical facilities across the United States. , General ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one ... its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design ... announced that it has been selected as a 2015 U.S.A. Taste Champion in the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric breast ... focus of numerous abstracts accepted for presentation here, at the 101st Annual Radiology ... highlight the use of Volpara Solutions’ quantitative breast imaging software tools for providing ...
Breaking Medicine News(10 mins):